![Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5a555ed4-a3e5-4796-bb30-d91663e54a7f/gr3_lrg.jpg)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial - The Lancet Haematology
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2018/07/lab-vienna-5.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-018-0048-9/MediaObjects/41408_2018_48_Fig1_HTML.jpg)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms | Blood Cancer Journal
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2018/07/lab-pavia-4.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6f6decec-32f9-4581-b839-c9be9b107269/ajh.v95.1.cover.jpg)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group - Mora - 2020 - American Journal of Hematology - Wiley Online Library
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2018/07/lab-pavia-2.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis | Bone Marrow Transplantation Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis | Bone Marrow Transplantation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41409-021-01305-x/MediaObjects/41409_2021_1305_Fig1_HTML.png)
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis | Bone Marrow Transplantation
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://universitiamo.eu/app/uploads/2019/04/Schermata-2019-04-09-alle-11.12.21-700x350.png)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/bb62d07f-fff9-4cf0-91b6-3f3a000ac101/bjh_6430_f2.gif)
The haematocrit and platelet target in polycythemia vera - Di Nisio - 2007 - British Journal of Haematology - Wiley Online Library
Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene | Haematologica
![Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/767a0afe-7118-4d4e-94b4-dd0b672b7186/ajh25545-fig-0001-m.jpg)
Facing erythrocytosis: Results of an international physician survey - Rumi - 2019 - American Journal of Hematology - Wiley Online Library
![PDF) Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis. A study of the MYSEC group PDF) Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis. A study of the MYSEC group](https://i1.rgstatic.net/publication/336311559_Impact_of_bone_marrow_fibrosis_grade_in_post-polycythemia_vera_and_post-essential_thrombocythemia_myelofibrosis_A_study_of_the_MYSEC_group/links/600fe967299bf14088c0d651/largepreview.png)
PDF) Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis. A study of the MYSEC group
![Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program | Blood Cancer Journal Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program | Blood Cancer Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41408-021-00445-z/MediaObjects/41408_2021_445_Fig2_HTML.png)
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program | Blood Cancer Journal
![Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo](https://img.youtube.com/vi/wm4V0TcS1pc/0.jpg)
Adopt a red blood cell: from Pavia to Vienna to Boston, the challenge of young investigators | Universitiamo
![Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT | Leukemia Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-021-01276-4/MediaObjects/41375_2021_1276_Fig1_HTML.png)